VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

T. pallidum Tp92 Protein Vaccine
Vaccine Information
  • Vaccine Name: T. pallidum Tp92 Protein Vaccine
  • Target Pathogen: Treponema pallidum
  • Target Disease: Syphilis
  • Vaccine Ontology ID: VO_0004026
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: 125 μg of purified intact ORF recombinant Tp92 (Cameron et al., 2000).
  • tp92 gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant: Ribi vaccine adjuvant
  • Immunization Route: i.m., s.c., i.p., and i.d.
Host Response

Rabbit Response

  • Host Strain: New Zealand White
  • Vaccination Protocol: New Zealand White rabbits were immunized (intramuscularly, subcutaneously, intraperitoneally, and intradermally) at 3‐week intervals with Ribi adjuvant and 125 μg of purified intact ORF recombinant Tp92. Unimmunized rabbits were used as a control (Cameron et al., 2000).
  • Challenge Protocol: At 1–4 weeks after administration of the final immunization in each protection experiment, the immunized rabbits and a total of 4 unimmunized control rabbits were subjected to intradermal challenge at each of 8 sites on their shaved backs with 105 T. pallidum subsp. pallidum (Nichols strain) per site. The rabbits were examined daily to monitor the development, morphologic appearance, and progression of lesions appearing at the challenge sites (Cameron et al., 2000).
  • Efficacy: Immunization with recombinant Tp92 partially protected rabbits from subsequent T. pallidum challenge. the rabbits immunized with the T. pallidum recombinant Tp92 before challenge all demonstrated alteration of lesion development. Significant attenuation of lesion development was observed in these rabbits, with atypical pale, flat, slightly indurated, and for the most part, nonulcerative lesions appearing at the sites of challenge. In these protection experiments, the number of lesions progressing to ulceration and the number of darkfield‐positive lesions in the Tp92‐immunized rabbits were significantly smaller than those of lesions appearing in the control animals (Cameron et al., 2000).
References
Cameron et al., 2000: Cameron CE, Lukehart SA, Castro C, Molini B, Godornes C, Van Voorhis WC. Opsonic potential, protective capacity, and sequence conservation of the Treponema pallidum subspecies pallidum Tp92. The Journal of infectious diseases. 2000; 181(4); 1401-1413. [PubMed: 10762571].